Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced a new exclusive Zingo(TM) marketing and distribution agreement, with Green Vision Company, for several Middle Eastern countries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the U.S. to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.

Green Vision is a pharmaceutical company headquartered in Qatar. The agreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates. Green Vision will be responsible for obtaining and maintaining product registrations in the licensed territories, as well as sales and marketing in the region. Terms of the agreement include an upfront payment, regulatory and sales milestones and royalty payments.

"This agreement further extends the potential markets for Zingo, a needle-free, local analgesic with a rapid onset of action, prior to peripheral venous access procedures in children, and is further validation of the unmet need Zingo addresses," said John P. McLaughlin, Anesiva's chief executive officer.

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local anesthesia to reduce the pain associated with peripheral IV insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo is approved in the U.S. to reduce the pain associated with peripheral IV insertions or blood draws in children three to 18 years of age. In clinical trials, the
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson ... three industry veterans to its equity research team ... "Our ongoing expansion in equity research demonstrates our ... unique insights to enhance their investment decision making," ... at STRH.  "We continue to make significant investments ...
(Date:8/28/2014)... 2014 Scientists, researchers, and technologists will ... Laser Damage 2014 symposium. Marking its 46th year, ... will run 14-17 September. The event is sponsored by ... . , The premier conference for basic and applied ... optical materials will engage researchers and engineers from numerous ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... to Initiate Phase II Trial for IPLEX(TM) in ... Sweden, Sept. 23 ,Insmed Inc. (Nasdaq CM: INSM), ... Premacure AB, a biopharmaceutical company,dedicated to the development ... to premature birth, today noted the presentation of,clinical ...
... REDWOOD CITY, Calif., Sept. 23 Codexis, Inc., ... Vice President,Intellectual Property. She will be responsible for ... portfolio and will,report to Douglas Sheehy, Vice President, ... Codexis from Danisco A/S, where as Senior,Director, Intellectual ...
... 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) today ... with Toray,Industries Inc. of Japan to obtain the ... Toraymyxin(TM), a therapeutic for the treatment of,sepsis that ... of the,agreement, the Company will seek FDA approval ...
Cached Biology Technology:Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 2Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 4Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 5Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... in their fight against a dangerous bacterium that sickens ... such as catheters, artificial joints and heart valves. , ... has, for the first time, been shown to protect ... would otherwise kill the bacteria, according to scientists at ...
... access publishing and the NIH new policy from ... of Health (NIH) rule on Enhanced Public Access to ... and a missed opportunity to take advantage of available ... the nation's leading not-for-profit medical and scientific publishers. The ...
... follow up of the NIH public access policy announced ... Central : , BioMed Central welcomes the announcement ... access policy. The NIH calls on all of its grantees ... National Library of Medicine's PubMed Central and make them freely ...
Cached Biology News:Substance protects resilient staph bacteria 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3BioMed Central welcomes the new National Institutes of Health public access policy 2
... IonQuest will provide great value plus ... detector has very high sensitivities and ... to the standard conductivity detector, the IonQuest ... as electrochemical, refractive index, UV/Visible, WaveQuest UV/Visible ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
Biology Products: